



CNS DISEASES

CNS Diseases Trials: the Julius Clinical Solution

Julius Clinical manages global clinical drug trials that will have a major impact on medicine and make a difference in patient care around the world.

Our unique combination of scientific leadership and operational excellence ensures that trial data is of the highest quality. Our internationally recognised academic leaders are actively involved in the design, conduct, and analysis of clinical trials. This scientific expertise and credibility combined with operational excellence means that we are uniquely equipped to assist in providing answers for today's clinical development challenges.

Neurological disorders consist of more than 600 conditions, impacting an estimated 75 million people worldwide every year. Many are rare disorders that affect a small number of patients who currently have access to few, if any, effective treatments.

Patient recruitment is, therefore, a huge challenge. Research in the CNS area is becoming a vibrant space with increased research spending in diseases such as Alzheimer's, ALS and Parkinson's. While there are many specialists in this area, the scientific understanding of the neurological basis of CNS disorders is not as advanced as some of the other physiological systems.

CNS DISEASES

The Challenges:

- Trials are lengthy and expensive
- Competitive trials for patient populations
- Global regional regulatory differences and requirements
- Endpoint subjectivity / Placebo noise

Our Solution:

- Flexible contract and payment options
- Expanded geographical footprint (including Latin America and global peer-to-peer networks)
- Deep in-house understanding of EU, Asia and Latin American regulatory processes and requirements
- Endpoint site-to-site standardisation and efficient trial design by Six Sigma Black Belt team

TRACK RECORD (a selection) | CNS DISEASES

STUDY	PERIOD	JC PATIENTS	THERAPEUTIC AREA
SAPHIR I	2014 - 2017	120	Alzheimer's Disease
SAPHIR II	Ongoing	Ongoing	Alzheimer's Disease
EUFEST	2003 - 2007	500	Schizophrenia
Efficacy and safety of novel products for ALS	Ongoing	240	Amyotrophic Lateral Sclerosis
Safety and efficacy study of products as add-on treatment in patients affected by ALS (IIT)	2018 - ongoing	440	Amyotrophic Lateral Sclerosis



Prof. Philip Scheltens, MD, PhD is Professor of Cognitive Neurology and Director of the Alzheimer Center at the VU University Medical Center in Amsterdam, as well as Honorary Professor of Neurology at University College London. He is also one of our Associated Scientists.



Broederplein 41-43
3703 CD Zeist
The Netherlands

+31 (0)30 656 99 00
info@juliusclinical.com
www.juliusclinical.com